{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:03:27Z","timestamp":1791925407599,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2023,11]]},"abstract":"\nBackground\/aims:<\/jats:title>\nHypertensive nephropathy (HN) is a kind of renal diseases caused by essential hypertension, eventually worsens into end-stage renal disease (ESRD). HN could damage the renal tubules, induce kidney damage, renal failure, and increase the risk of stroke, heart disease or death, but there are few ideal drugs for HN treatment.<\/jats:p>\n<\/jats:sec>\n\nMethods:<\/jats:title>\nIn this study, we explored the therapeutic effect of bajijiasu (a compound from Morinda officinalis how and a common traditional Chinese medicine for tonifying the kidney) on the HN rat model. Biochemical analysis, HE staining, and PAS staining were used to assess the effects of bajijiasu on HN rat model, western blotting was used to analyze the potential mechanisms.<\/jats:p>\n<\/jats:sec>\n\nResults:<\/jats:title>\nThe results of HE staining and PAS staining showed that bajijiasu could alleviate the pathological\nchanges in HN rat models; biochemical analysis found that the concentration of Malondialdehyde\n(MDA), total protein (TP), albumin (ALB), microalbuminuria (MALB), blood urea nitrogen\n(BUN), creatinine (Cr), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) were\nsignificantly decreased compared with the model group after bajijiasu treatment; and bajijiasu could\nregulate the expression of TNF-\u03b1, IL-6, MDA, SOD1 and AGEs in HN rats; the result of western\nblotting demonstrated that bajijiasu could down-regulate the expression of TGF\u03b21, NOX4, JNK, p-\nJNK and up-regulate the expression PPAR\u03b3 and SOD 1 in HN rats.<\/jats:p>\n<\/jats:sec>\n\nConclusion:<\/jats:title>\nThose results demonstrated that bajijiasu could alleviate the pathological changes, physiological and biochemical symptoms of HN rat models by regulating the expression of TGF\u03b21, PPAR\u03b3, JNK, p-JNK, NOX4 and SOD1, but could not lower the blood pressure of HN rats. Those evidences may provide a new therapeutic method for HN treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874467215666221005141210","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:28:26Z","timestamp":1665055706000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Protective Effect of Bajijiasu on the Treatment of Hypertensive\nNephropathy in Rats"],"prefix":"10.1016","volume":"16","author":[{"given":"Junzheng","family":"Yang","sequence":"first","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghai","family":"Li","sequence":"first","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyi","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beifeng","family":"Lie","sequence":"additional","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Duan","sequence":"additional","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xia","sequence":"additional","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xie","sequence":"additional","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Institute of Consun Co. for Chinese Medicine in Kidney Diseases, Guangdong Consun Pharmaceutical Group, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113146","volume":"10","author":"Costantino V.V.","year":"2021","unstructured":"Costantino V.V.; Gil Lorenzo A.F.; Bocanegra V.; Vallés P.G.; Molecular mechanisms of hypertensive nephropathy: Renoprotective effect of losartan through Hsp70. Cells 2021,10(11)","journal-title":"Cells"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2010.154","volume":"7","author":"Udani S.","year":"2011","unstructured":"Udani S.; Lazich I.; Bakris G.L.; Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011,7(1),11-21","journal-title":"Nat Rev Nephrol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrneph.2015.172","volume":"12","author":"Freedman B.I.","year":"2016","unstructured":"Freedman B.I.; Cohen A.H.; Hypertension attributed nephropathy: What\u2019s in a name? Nat Rev Nephrol Available from: 2016,12,27-36","journal-title":"Nat Rev Nephrol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.109.133777","volume":"54","author":"Bidani A.K.","year":"2009","unstructured":"Bidani A.K.; Griffin K.A.; Williamson G.; Wang X.; Loutzenhiser R.; Protective importance of the myogenic response in the renal circulation. Hypertension 2009,54,393-398","journal-title":"Hypertension"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejphar.2018.06.010","volume":"833","author":"Zhang C.","year":"2018","unstructured":"Zhang C.; Booz G.W.; Yu Q.; He X.; Wang S.; Fan F.; Conflicting roles of 20-HETE in hypertension and renal end organ damage. Eur J Pharmacol 2018,833,190-200","journal-title":"Eur J Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/1753944715597623","volume":"9","author":"Mendoza-Torres E.","year":"2015","unstructured":"Mendoza-Torres E.; Oyarzún A.; Mondaca-Ruff D.; Azocar A.; Castro P.F.; Jalil J.E.; Chiong M.; Lavandero S.; Ocaranza M.P.; ACE2 and vasoactive peptides: Novel players in cardiovascular\/renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015,9(4),217-237","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/HJH.0000000000001170","volume":"35","author":"Seccia T.M.","year":"2017","unstructured":"Seccia T.M.; Caroccia B.; Calò L.A.; Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens 2017,35(2),205-212","journal-title":"J Hypertens"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1517\/14656566.2010.485612","volume":"11","author":"Hart P.D.","year":"2010","unstructured":"Hart P.D.; Bakris G.L.; Hypertensive nephropathy: Prevention and treatment recommendations. Expert Opin Pharmacother 2010,11(16),2675-2686","journal-title":"Expert Opin Pharmacother"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/molecules14062049","volume":"14","author":"Li N.","year":"2009","unstructured":"Li N.; Qin L.P.; Han T.; Wu Y.B.; Zhang Q.Y.; Zhang H.; Inhibitory effects of morinda officinalis extract on bone loss in ovariectomized rats. Molecules 2009,14(6),2049-2061","journal-title":"Molecules"},{"key":"ref=10","first-page":"1084","volume":"22","author":"Li Y.F.","year":"2001","unstructured":"Li Y.F.; Yuan L.; Xu Y.K.; Yang M.; Zhao Y.M.; Luo Z.P.; Antistress effect of oligosaccharides extracted from Morinda officinalis in mice and rats. Acta Pharmacol Sin 2001,22(12),1084-1088","journal-title":"Acta Pharmacol Sin"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.lfs.2004.02.029","volume":"75","author":"Li Y.F.","year":"2004","unstructured":"Li Y.F.; Liu Y.Q.; Yang M.; Wang H.L.; Huang W.C.; Zhao Y.M.; Luo Z.P.; The cytoprotective effect of inulin-type hexasaccharide extracted from Morinda officinalis on PC12 cells against the lesion induced by corticosterone. Life Sci 2004,75(13),1531-1538","journal-title":"Life Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3969\/j.issn.1001-1978.2013.02.28","volume":"29","author":"Chen D.L.","year":"2013","unstructured":"Chen D.L.; Zhang P.; Lin L.; Zhang H.M.; Liu S.H.; Effect of oligosaccharides from Morinda officinalis on β-amyloid-induced learning and memory dysfunction in rats. Chin Pharmacol Bull 2013,29,273-276","journal-title":"Chin Pharmacol Bull"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3389\/fnagi.2017.00403","volume":"9","author":"Chen D.","year":"2017","unstructured":"Chen D.; Yang X.; Yang J.; Lai G.; Yong T.; Tang X.; Shuai O.; Zhou G.; Xie Y.; Wu Q.; Prebiotic effect of fructooligosaccharides from Morinda officinalis on Alzheimer\u2019s disease in rodent models by targeting the microbiota-gut-brain axis. Front Aging Neurosci 2017,9,403","journal-title":"Front Aging Neurosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e13509","DOI":"10.1111\/and.13509","volume":"52","author":"Abarikwu S.O.","year":"2020","unstructured":"Abarikwu S.O.; Onuah C.L.; Singh S.K.; Plants in the management of male infertility. Andrologia 2020,52(3),e13509","journal-title":"Andrologia"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jep.2015.02.016","volume":"164","author":"Wu Z.Q.","year":"2015","unstructured":"Wu Z.Q.; Chen D.L.; Lin F.H.; Lin L.; Shuai O.; Wang J.Y.; Qi L.K.; Zhang P.; Effect of bajijiasu isolated from Morinda officinalis F. C. how on sexual function in male mice and its antioxidant protection of human sperm. J Ethnopharmacol 2015,164,283-292","journal-title":"J Ethnopharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/13880209.2019.1582679","volume":"57","author":"Yang X.","year":"2019","unstructured":"Yang X.; Hu G.; Lv L.; Liu T.; Qi L.; Huang G.; You D.; Zhao J.; Regulation of P-glycoprotein by Bajijiasu in vitro and in vivo by activating the Nrf2-mediated signalling pathway. Pharm Biol 2019,57(1),184-192","journal-title":"Pharm Biol"},{"key":"ref=17","first-page":"321","volume":"21","author":"Cai B.","year":"2005","unstructured":"Cai B.; Cui C.B.; Chen Y.H.; Evaluation of antidepressant effect of bajitian, a traditional chinese medicine from the roots of Morinda officinalis. How, in mouse and rat models. Pharm J Chin PLA 2005,21,321-325","journal-title":"Pharm J Chin PLA"},{"key":"ref=18","first-page":"216","volume":"33","author":"Li X.J.","year":"2017","unstructured":"Li X.J.; Xu K.; Shi Y.Y.; Xie Y.; Clinical trial of bajitian oligosaccharide capsules in the treatment of depression. Chin J Clin Pharm 2017,33,216-221","journal-title":"Chin J Clin Pharm"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/ijms18010203","volume":"18","author":"Hong G.","year":"2017","unstructured":"Hong G.; Zhou L.; Shi X.; He W.; Wang H.; Wei Q.; Chen P.; Qi L.; Tickner J.; Lin L.; Xu J.; Bajijiasu abrogates osteoclast differentiation via the suppression of RANKL signaling pathways through NF-κB and NFAT. Int J Mol Sci 2017,18(1),203","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jep.2017.10.028","volume":"213","author":"Zhang J.","year":"2018","unstructured":"Zhang J.; Xin H.; Xu Y.; Shen Y.; He Y.Q.; Hsien-Yeh; Lin, B.; Song, H.; Juan-Liu; Yang, H.; Qin, L.; Zhang, Q.; Du, J. Morinda officinalis How. - A comprehensive review of traditional uses, phytochemistry and pharmacology. J Ethnopharmacol 2018,213,230-255","journal-title":"J Ethnopharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.fitote.2016.03.013","volume":"110","author":"Zhang Z.","year":"2016","unstructured":"Zhang Z.; Zhang Q.; Yang H.; Liu W.; Zhang N.; Qin L.; Xin H.; Monotropein isolated from the roots of Morinda officinalis increases osteoblastic bone formation and prevents bone loss in ovariectomized mice. Fitoterapia 2016,110,166-172","journal-title":"Fitoterapia"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jep.2014.04.004","volume":"154","author":"Chen D.L.","year":"2014","unstructured":"Chen D.L.; Zhang P.; Lin L.; Zhang H.M.; Deng S.D.; Wu Z.Q.; Ou S.; Liu S.H.; Wang J.Y.; Protective effects of bajijiasu in a rat model of Aβ25\u201335-induced neurotoxicity. J Ethnopharmacol 2014,154,206-217","journal-title":"J Ethnopharmacol"},{"key":"ref=23","first-page":"1733","volume":"48","author":"Zou Z.J.","year":"2013","unstructured":"Zou Z.J.; Xie Y.Y.; Gong M.J.; Han B.; Wang S.M.; Liang S.W.; Urine metabonomic study of intervention effects of Morinda officinalis how. on \u2018kidney-yang deficiency syndrome\u2019. Yao Xue Xue Bao 2013,48(11),1733-1737","journal-title":"Yao Xue Xue Bao"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"92621","DOI":"10.18632\/oncotarget.21515","volume":"8","author":"Cai H.","year":"2017","unstructured":"Cai H.; Wang Y.; He J.; Cai T.; Wu J.; Fang J.; Zhang R.; Guo Z.; Guan L.; Zhan Q.; Lin L.; Xiao Y.; Pan H.; Wang Q.; Neuroprotective effects of bajijiasu against cognitive impairment induced by amyloid-β in APP\/PS1 mice. Oncotarget 2017,8(54),92621-92634","journal-title":"Oncotarget"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"111941","DOI":"10.1016\/j.biopha.2021.111941","volume":"141","author":"Du H.","year":"2021","unstructured":"Du H.; Xiao G.; Xue Z.; Li Z.; He S.; Du X.; Zhou Z.; Cao L.; Wang Y.; Yang J.; Wang X.; Zhu Y.; QiShenYiQi ameliorates salt-induced hypertensive nephropathy by balancing ADRA1D and SIK1 expression in Dahl salt-sensitive rats. Biomed Pharmacother 2021,141,111941","journal-title":"Biomed Pharmacother"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8472963","volume":"2018","author":"Yan D.","year":"2018","unstructured":"Yan D.; Yue B.; Qian M.; Zhao L.; Zhang Z.; Qian H.; Yan S.; Qian Y.; Fang Z.; JYYS granule mitigates renal injury in clinic and in spontaneously hypertensive rats by inhibiting NF-κ B signaling-mediated microinflammation. Evid Based Complement Alternat Med 2018,2018,1-13","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fphar.2021.667433","author":"Qian L.","year":"2021","unstructured":"Qian L.; Ren S.; Xu Z.; Zheng, Y Qian Yang Yu Yin Granule improves renal injury of hypertension by regulating metabolic reprogramming mediated by HIF-1α\/PKM2 positive feedback loop. Front Pharmacol 2021,12","journal-title":"Front Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/009127009203200605","volume":"32","author":"Achari R.","year":"1992","unstructured":"Achari R.; Laddu A.; Terazosin: A new alpha adrenoceptor blocking drug. J Clin Pharmacol 1992,32(6),520-523","journal-title":"J Clin Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/0003319708326450","volume":"60","author":"Papadopoulos D.P.","year":"2009","unstructured":"Papadopoulos D.P.; Papademetriou V.; Metoprolol succinate combination in the treatment of hypertension. Angiology 2009,60(5),608-613","journal-title":"Angiology"},{"key":"ref=30","first-page":"249","volume":"271","author":"Miyagishi A.","year":"1984","unstructured":"Miyagishi A.; Nakahara H.; Hara Y.; Adrenoceptor blocking effects of arotinolol, a new combined alpha- and beta-adrenoceptor blocking agent. Arch Int Pharmacodyn Ther 1984,271(2),249-262","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14740338.2018.1397129","volume":"17","author":"Elliott W.J.","year":"2018","unstructured":"Elliott W.J.; Bistrika E.A.; Perindopril arginine and amlodipine besylate for hypertension: A safety evaluation. Expert Opin Drug Saf 2018,17(2),207-216","journal-title":"Expert Opin Drug Saf"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/erc.10.163","volume":"9","author":"Ram C.V.S.","year":"2011","unstructured":"Ram C.V.S.; Ram S.; Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. Expert Rev Cardiovasc Ther 2011,9(1),9-19","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/22953337.1982.11718860","volume":"37","author":"Staessen J.","year":"1982","unstructured":"Staessen J.; Fagard R.; Lijnen P.; Amery A.; Captopril in the treatment of hypertension. Acta Clin Belg 1982,37(3),164-184","journal-title":"Acta Clin Belg"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s10020-021-00408-x","volume":"27","author":"Weng H.C.","year":"2021","unstructured":"Weng H.C.; Lu X.Y.; Xu Y.P.; Wang Y.H.; Wang D.; Feng Y.L.; Chi Z.; Yan X.Q.; Lu C.S.; Wang H.W.; Fibroblast growth factor 21 attenuates salt-sensitive hypertension-induced nephropathy through anti-inflammation and anti-oxidation mechanism. Mol Med 2021,27(1),147","journal-title":"Mol Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"F689","DOI":"10.1152\/ajprenal.00502.2015","volume":"310","author":"Chang A.S.","year":"2016","unstructured":"Chang A.S.; Hathaway C.K.; Smithies O.; Kakoki M.; Transforming growth factor-β1 and diabetic nephropathy. Am J Physiol Renal Physiol 2016,310(8),F689-F696","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fimmu.2018.00745","volume":"13","year":"2018","unstructured":"Alexandre Crosstalk between peroxisome proliferator-activated receptor gamma and the canonical WNT\/β-catenin pathway in chronic inflammation and oxidative stress during carcinogenesis. Front Immunol Vallée2018,13,745","journal-title":"Front Immunol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s11033-018-4421-3","volume":"45","author":"Gill B.S.","year":"2018","unstructured":"Gill B.S.; Mehra R.; Navgeet; Kumar, S. Vitex negundo and its medicinal value. Mol Biol Rep 2018,45(6),2925-2934","journal-title":"Mol Biol Rep"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3892\/or.12.4.921","volume":"12","author":"Huang J.","year":"2004","unstructured":"Huang J.; Tan P.; Tan B.; Bay B.; GST-pi expression correlates with oxidative stress and apoptosis in breast cancer. Oncol Rep 2004,12(4),921-925","journal-title":"Oncol Rep"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874467215666221005141210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209617\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874467215666221005141210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:58:19Z","timestamp":1746572299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209617\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467215666221005141210","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e051022209617"}}